Cerity Partners LLC Invests $573,000 in LivaNova PLC (NASDAQ:LIVN)

Cerity Partners LLC bought a new position in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 10,907 shares of the company's stock, valued at approximately $573,000.

A number of other institutional investors also recently bought and sold shares of the company. Point72 Asset Management L.P. increased its position in shares of LivaNova by 204.3% during the second quarter. Point72 Asset Management L.P. now owns 1,285,636 shares of the company's stock valued at $70,479,000 after acquiring an additional 863,157 shares during the last quarter. First Light Asset Management LLC increased its position in shares of LivaNova by 591.1% during the second quarter. First Light Asset Management LLC now owns 710,390 shares of the company's stock valued at $38,944,000 after acquiring an additional 607,598 shares during the last quarter. Great Lakes Advisors LLC acquired a new stake in shares of LivaNova during the second quarter valued at about $16,614,000. Driehaus Capital Management LLC increased its position in shares of LivaNova by 64.7% during the second quarter. Driehaus Capital Management LLC now owns 544,042 shares of the company's stock valued at $29,824,000 after acquiring an additional 213,749 shares during the last quarter. Finally, Perceptive Advisors LLC increased its position in shares of LivaNova by 48.5% during the second quarter. Perceptive Advisors LLC now owns 444,000 shares of the company's stock valued at $24,340,000 after acquiring an additional 145,000 shares during the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

LivaNova Stock Down 1.6 %

NASDAQ LIVN traded down $0.79 on Friday, hitting $49.71. 504,805 shares of the stock were exchanged, compared to its average volume of 417,894. The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46. LivaNova PLC has a fifty-two week low of $43.15 and a fifty-two week high of $64.47. The company has a market cap of $2.70 billion, a PE ratio of 118.36 and a beta of 0.98. The company has a 50-day moving average price of $52.19 and a 200-day moving average price of $51.74.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the stock. Robert W. Baird lifted their price target on shares of LivaNova from $66.00 to $72.00 and gave the company an "outperform" rating in a research report on Thursday, October 31st. StockNews.com cut shares of LivaNova from a "strong-buy" rating to a "buy" rating in a research report on Saturday, November 16th. Mizuho dropped their price target on shares of LivaNova from $80.00 to $70.00 and set an "outperform" rating for the company in a research report on Thursday, October 31st. Baird R W upgraded shares of LivaNova from a "hold" rating to a "strong-buy" rating in a report on Tuesday, September 17th. Finally, The Goldman Sachs Group started coverage on shares of LivaNova in a report on Friday, October 4th. They issued a "buy" rating and a $65.00 price objective for the company. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $69.17.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.